Herishanu Y, et al. - In this study, researchers estimated 40 candidates to examine the efficiency and tolerability of lower-dose fludarabine and cyclophosphamide combined with a standard dose of rituximab (LD-FCR) in elderly subjects with previously untreated chronic lymphocytic leukemia (CLL). They observed the overall response and complete response rates, 67.5% and 42.5%, respectively. They noted 35.5 months, median progression-free survival (PFS) and death of 2 candidates during the study period. They recorded hematological toxicities and infections, the most frequent complications encountered with grade 3 to 4 treatment-related neutropenia in 47.6% of cases. They also concluded LD-FCR with the advantage of being both "time and cost limited".